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The serine/threonine kinase Akt is frequently activated in
human cancers and is considered an attractive therapeutic
target. However, the relative contributions of the different
Akt isoforms to tumorigenesis, and the effect of their
deﬁciencies on cancer development are not well under-
stood. We had previously shown that Akt1 deﬁciency is
sufﬁcient to markedly reduce the incidence of tumors
in Pten
þ/  mice. Particularly, Akt1 deﬁciency inhibits
endometrial carcinoma and prostate neoplasia in Pten
þ/ 
mice. Here, we analyzed the effect of Akt2 deﬁciency
on the incidence of tumors in Pten
þ/  mice. Relative to
Akt1, Akt2 deﬁciency had little-to-no effect on the
incidence of prostate neoplasia, endometrial carcinoma,
intestinal polyps and adrenal lesions in Pten
þ/  mice.
However, Akt2 deﬁciency signiﬁcantly decreased the
incidence of thyroid tumors in Pten
þ/ , which correlates
with the relatively high level of Akt2 expression in the
thyroid. Thus, unlike Akt1 deletion, Akt2 deletion is not
sufﬁcient to markedly inhibit tumorigenesis in Pten
þ/ 
mice in most tested tissues. The relatively small effect
of Akt2 deletion on the inhibition of tumorigenesis in
Pten
þ/  mice could be explained, in part, by an
insufﬁcient decrease in total Akt activity, due to the
relatively lower Akt2 versus Akt1 expression, and relatively
high blood insulin levels in Pten
þ/ Akt2
 /  mice. The
relatively high blood insulin levels in Pten
þ/ Akt2
 / 
m i c em a ye l e v a t et h ea c t i v i t yo fA k t 1 ,a n dp o s s i b l yA k t 3 ,
thus, limiting the reduction of total Akt activity and
preventing this activity from dropping to a threshold level
required to inhibit tumorigenesis.
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Introduction
The tumor suppressor phosphatase and tensin homolog
(PTEN) is a phospholipid phosphatase that negates the
activity of phosphatidylinositol 3-kinase by de-phos-
phorylating the D3 position of the inositol ring of
phosphoinositides phosphorylated by phosphatidylino-
sitol 3-kinase. Inactivation of PTEN occurs frequently
in human cancers, particularly in prostate carcinoma,
endometrial carcinoma and glioblastoma (Cairns et al.,
1997; Cantley and Neel, 1999; Muller et al., 2000;
Mutter et al., 2000; Parsons and Simpson, 2003).
Pten
þ/  mice recapitulate PTEN deﬁciency in human
cancer as manifested by the high incidence of high-grade
prostate intraepithelial neoplasia (PIN), and endome-
trial carcinoma in these mice (Di Cristofano et al., 1998;
Suzuki et al., 1998; Podsypanina et al., 1999; Stambolic
et al., 2000; Chen et al., 2006). In addition, Pten
þ/  mice
develop a high incidence of adrenal medullary neoplasia,
thyroid neoplasia, intestinal polyps and lymphoid
hyperplasia (Chen et al., 2006).
A major downstream effector of PTEN is Akt, which
is hyperactivated by PTEN deﬁciency. Mammalian
cells have three genes that encode three Akt isoforms
(Akt1–3). The three Akt isoforms have a high degree of
amino acid sequence identity, and appear to have similar
kinase speciﬁcity in in vitro kinase assays (Walker et al.,
1998). The individual Akt isoform knockout mice
display different phenotypes, which could be explained
by the relative expression of the three Akt isoforms in
the affected tissues and organs (reviewed in (Bhaskar
and Hay, 2007)). However, isoform-speciﬁc function
of the different Akt isoforms cannot be completely
excluded. Indeed, it was reported that Akt1 and Akt2
might be functionally different with respect to cell
invasion, migration and metastasis (Bhaskar and Hay,
2007). It was also reported recently that different Akt
isoforms regulate distinct subsets of microRNAs (Ilio-
poulos et al., 2009), and that the actin-bundling protein,
palladin, is a speciﬁc substrate of Akt1 and not of Akt2
(Chin and Toker, 2010). The deletion of Akt1 in mice
does not elicit any major severe physiological con-
sequences (Chen et al., 2001; Cho et al., 2001b). The
deletion of Akt2 elicits insulin resistance with a
signiﬁcant elevation of insulin levels (Cho et al., 2001a;
Garofalo et al., 2003; Chen et al., 2009), but the
haploinsufﬁciency Akt1 together with Akt2 deﬁciency
elicits a severe diabetic phenotype (Chen et al., 2009).
Because Akt is an attractive target for cancer therapy,
and Akt-isoform-speciﬁc inhibitors are being developed
(Li et al., 2009; Lindsley, 2010), it is important to know
the effect of Akt-isoform-speciﬁc inhibition on tumor
development.
Previously, we had shown that Akt1 deﬁciency is
sufﬁcient to inhibit all the neoplastic lesions developed
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þ/  mice. Even haplodeﬁciency of Akt1 was
sufﬁcient to attenuate signiﬁcantly the development of
high-grade PIN and endometrial carcinoma in Pten
þ/ 
mice (Chen et al., 2006). Akt1 deﬁciency is also sufﬁcient
to inhibit skin carcinogensis, and salivary and mammary
gland tumors developed in MMTV-Ras and MMTV-
neu mice (Skeen et al., 2006; Ju et al., 2007). However,
unlike Akt1 deletion, the deletion of Akt2 does not
appear to inhibit mammary gland tumorigenesis, and
even accelerates it (Maroulakou et al., 2007). Here, we
examined the effect of Akt2 deﬁciency on the develop-
ment of tumors in Pten
þ/  mice. We found that in
most tested tissues, Akt2 deletion did not inhibit
tumorigenesis. Although Akt2 is expressed to a lesser
extent than Akt1 in these tissues, this reduced expression
cannot fully explain why the deletion of Akt2 was not
sufﬁcient to attenuate the development of tumors
inhibited by Akt1 deletion in Pten
þ/  mice. We propose
that the relatively high level of blood insulin in Pten
þ/ 
Akt2
 /  mice prohibits the reduction of total Akt
activity to a threshold level required to inhibit tumor-
igenesis by elevating the activity of other Akt isoforms.
Results
Akt2 deﬁciency does not inhibit the development
of high-grade PIN in PTEN heterozygous mice
Pten
þ/  male mice have high incidence of high-grade
PIN when they reach 1 year of age (Chen et al., 2006).
We determined the development of PIN in the three
mouse prostate lobes of 12-month-old Pten
þ/–, Pten
þ/–
Akt2
–/– mice using histopathological criteria and bromo-
deoxyuridine (BrdU) incorporation as previously described
(Chen et al., 2006). High-grade lesions (PIN3 and PIN4)
were monitored as previously described (Chen et al.,
2006). In the anterior lobe of Pten
þ/  mice, we
observed 100% incidence of PIN4 lesions, which was
not affected by Akt2
 /  deletion (Figure 1a). In the
dorsolateral lobe we observed about 25% incidence
of PIN3 lesions and about 75% incidence of PIN4
lesions. In the dorsolateral lobe of Pten
þ/ Akt2
 /  mice,
there was about 30% incidence of PIN3 and 70%
incidence of PIN4 lesions. The incidence of PIN4 lesions
in the ventral lobe was close to 100% and was only
slightly decreased by Akt2
 /  deletion, which also
slightly increased the incidence of PIN3 lesions. Overall,
Akt2 deletion does not appear to markedly affect the
development and incidence of high-grades PIN in the
prostate of Pten
þ/  mice. These results were corrobo-
rated by the examination of BrdU incorporation
that showed no signiﬁcant difference between Pten
þ/ 
and Pten
þ/ Akt2
 /  prostates (Figure 1b). In normal
prostate, keratin 14 (K14) can only be detected in basal
cells and is absent in the luminal epithelium. It was
shown, however, that high-grade PIN in Pten
þ/  mice
are characterized by increased expression of K14 in
the lumen (Park et al., 2002). In our previous analysis
we established intense K14 staining as independent
criterion for high-grade PIN in the mouse prostate.
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Figure 1 Akt2 deﬁciency does not impair the development of high-grade PIN in Pten
þ/– mice. (a) Incidence of PIN3 and PIN4 lesions
in the three prostate lobes (A, anterior, DL, dorsolateral and V, ventral) of Pten
þ/– and Pten
þ/–Akt2
–/– mice. The numbers of mice in
each group are indicated. (b) BrdU incorporation in the prostate lobes of Pten
þ/– and Pten
þ/–Akt2
–/– mice. The numbers of mice in each
group are indicated in parentheses. BrdU-positive cells were counted as described in Materials and methods. P-values were calculated
for each prostate lobe in each genotype. (c) Quantiﬁcation of K14 staining, from ﬁve mice of each genotype as described in Materials
and methods.
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OncogeneIn the normal prostate, K14-positive cells were conﬁned
to the basal layer, whereas in high-grade PIN, there were
many large K14-positive cells in the lumen of the duct
(Chen et al., 2006). We therefore monitored the staining
for K14 and found that it corroborated the histopatho-
logical analyses and the BrdU incorporation (Figure 1c).
In contrast to the Akt2 deletion, we had shown
previously that Akt1 deletion decreased the incidence
of PIN4 lesions in the anterior and dorsolateral lobes
of the prostate in Pten
þ/  mice by a 7- to 8-fold factor,
and completely diminished the incidence of high-grade
PIN in the ventral lobe. Even the haplodeﬁciency of
Akt1 decreased the incidence of PIN4 lesions in the
prostate of Pten
þ/  mice by a factor of 2 to 4 (Chen
et al., 2006).
Akt2 deﬁciency is not sufﬁcient to inhibit the development
of endometrial carcinoma in Pten
þ/– mice
PTEN dysfunction is one of the most frequently
occurring genetic lesions in endometrial carcinoma
(Tashiro et al., 1997). Female Pten
þ/– mice have a high
incidence of endometrial neoplasia by 9 months of age.
The development of severe lymphoid hyperplasia in
Pten
þ/– female mice ultimately leads to their death
before 1 year of age (Di Cristofano et al., 1998, 2001;
Podsypanina et al., 1999; Stambolic et al., 2000),
precluded analysis of older female mice.
Previously (Chen et al., 2006), we classiﬁed endome-
trial epithelial lesions in the endometrium of Pten
þ/ 
mice as simple hyperplasia, mild atypical hyperplasia,
moderate atypical hyperplasia, complex atypical hyper-
plasia and focal carcinoma in situ (CIS) ((Chen et al.,
2006), Figure 2a). In our current histopathological
analyses of 9-month-old female mice, we found that
out of 43 Pten
þ/  mice, 24 (about 56%) display the
highest grade as CIS, and 10 (about 23%) the highest
grade as AH3. Out of 36 Pten
þ/ Akt2
 /  mice, 18
(50%) display CIS and 9 (about 25%) display AH3
(Figure 2b). Though the incidence of CIS is slightly
lower in Pten
þ/ Akt2
 /  mice, overall, Akt2 deletion
does not appear to inhibit the development of the
neoplastic lesions in the endometrium of Pten
þ/  mice.
The histopathological results were corroborated by the
analysis of BrdU incorporation (Figure 2c). In contrast
to these results, our previous analyses showed that
the deletion of Akt1 reduced the incidence of endo-
metrial CIS in Pten
þ/  mice by almost fourfold. Even
haplodeﬁciency of Akt1 was sufﬁcient to reduce the
incidence of endometrial CIS more than twofold (Chen
et al., 2006).
The effect of Akt2 deﬁciency on the development of
adrenal medullary neoplasia and intestinal polyps in
Pten
þ/– mice
Both female and male Pten
þ/  mice develop bilateral
adrenal medullary tumors (Chen et al., 2006). In our
previous studies we found that the size of the adrenal
medulla, which was directly correlated with the size and
grade of the tumors in Pten
þ/– mice, was signiﬁcantly
decreased in Pten
þ/–Akt1
–/– mice (Chen et al., 2006). We
therefore quantiﬁed the diameter of the adrenal medulla
as an indirect measure of tumor size. In both female and
male mice, the deﬁciency of Akt2 slightly decreased the
diameter of the adrenal medulla in Pten
þ/  mice.
However, unlike the deletion of Akt1 that signiﬁcantly
reduced BrdU incorporation in the adrenal glands of
Pten
þ/  mice (Chen et al., 2006), the reduction of BrdU
incorporation by Akt2 deletion is not signiﬁcant, and
no signiﬁcant change in mitotic index was observed
(Figure 3b, and data not shown).
As was previously shown, Pten
þ/  mice have a high
incidence of intestinal polyps. These polyps seemed to be
adenomatous polyps (tubular adenoma) or hamartoma-
tous polyps, and their incidence was signiﬁcantly
reduced by the deletion of and even by the haplodeﬁ-
ciency of Akt1 in Pten
þ/  mice (Chen et al., 2006). In
our current analyses, we found that 12-month-old male
and 9-month-old female Pten
þ/  mice develop intestinal
polyps with B80% and 90% incidence, respectively,
similar to previous observations (Chen et al., 2006).
This incidence, however, was not signiﬁcantly decreased
by the deletion of Akt2. Quantiﬁcation of the average
number of polyps per mouse did not show a statis-
tically signiﬁcant decrease in Pten
þ/ Akt2
 /  mice
(Figure 3c). In contrast, both haplodeﬁciency and a
complete deletion of Akt1 in Pten
þ/  mice reduced the
average number of polyps per mouse substantially
(Chen et al., 2006).
Akt2 deﬁciency inhibits the development of thyroid tumors
in Pten
þ/  mice
Previous studies showed a high incidence of thyroid
tumors in Pten
þ/  mice (Podsypanina et al., 1999;
Chen et al., 2006). Two major neoplastic lesions were
deﬁned. Transformed glands that tend to blend into
the surrounding normal-looking thyroid follicles were
deﬁned as separated transformed glands. Aggregated
transformed glands with nodule formation that, based
on their morphology, are consistent with thyroid
adenomatoid nodules or multiple adenomas were
deﬁned as tumors (Chen et al., 2006). Previous
examination of 11-month-old Pten
þ/  male mice found
that 80% of the mice developed thyroid tumors, and
20% of the mice developed separated transformed
glands, which is the lower grade lesion. The deletion
of Akt1 reduced by almost twofold the incidence of
thyroid tumors in Pten
þ/  mice (Chen et al., 2006).
In our current studies we found consistently that 75%
of 12-month-old Pten
þ/  male mice developed thyroid
tumors and 25% developed only separated transformed
glands (Figure 4). The deletion of Akt2 in Pten
þ/ 
male mice reduced the percentage of mice with tumors
to 42%, but the percentage of mice with separated
transformed glands was increased to 40%, and 18%
of Pten
þ/ Akt2
 /  mice were free of any neoplastic
lesion (Figure 4). In 9-month-old female Pten
þ/ , the
deletion of Akt2 decreases the percentage of mice with
tumors from about 53% to about 42% (Figure 4). These
results are very similar to those obtained with Akt1
deletion (Chen et al., 2006), indicating that the deletion
of either Akt1 or Akt2 reduced thyroid tumorigenicity
in Pten
þ/  mice to the same extent.
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OncogeneThe deletion of Akt2 in Pten
þ/  mice did not
signiﬁcantly reduce total Akt activity, except in the
thyroid
To understand why Akt2 deletion has only minimal
effect on tumorigenesis in Pten
þ/  mice, we examined
the effect of Akt2 deletion on total Akt activity.
Surprisingly we did not ﬁnd any signiﬁcant reduction in
total Akt activity after the deletion of Akt2 in Pten
þ/ 
prostate, uterus and adrenal glands (Figures 5a, b and
d). We previously showed strong pAkt immunostaining
on the plasma membrane of cells in histological sections
of high-grade neoplastic lesions in the prostate of
Pten
þ/  mice (Chen et al., 2006). However, strong
plasma membrane staining of pAkt was not diminished
in histological sections derived from Pten
þ/ Akt2
 / 
prostate (Figure 5a, left panel). In contrast to the
prostate, uterus and adrenal, we observed a decrease
of about 50% in total Akt activity in the thyroid
(Figures 5c and d). Thus, the effect of Akt2 deletion
on tumorigenesis in Pten
þ/  mice could be directly
correlated to its effect on the reduction of total Akt
activity.
Previously, we analyzed by quantitative RT–PCR the
relative expression of Akt1 and Akt2 (Chen et al., 2006),
shown in Figure 5e, as a Akt1/Akt2 ratio. On the basis
of this ratio, deletion of Akt2 can be expected to reduce
total Akt activity by about 30% in the uterus, by close
to 40% in the prostate, by close to 50% in the adrenal
glands and by about 70% in the thyroid. Thus, total Akt
activity was not decreased to the level expected from the
Figure 2 Akt2 deﬁciency is insufﬁcient to inhibit the development of endometrial carcinoma in Pten
þ/– mice. (a) Histological sections
representing the different grades of endometrial neopplasia in Pten
þ /  mice (AH, atypical hyperplasia, CIS, carcinoma in situ). The
source of the tissue sections is indicated. (b) Incidence of endometrial neoplasia in Pten
þ/–, Pten
þ/–Akt2
–/– and wild-type mice. Total
number of mice examined in each group is indicated in parentheses. (c) BrdU incorporation in the uteri of Pten
þ/–, Pten
þ/–Akt2
–/– and
wild-type mice. The numbers of mice in each group are indicated in parentheses. P-values are indicated.
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Oncogenerelative expression of Akt2. However, when the im-
munoblot was subjected to pan-Akt antibodies, we did
not observe the expected decrease in total Akt in all
tissues in which Akt2 was deleted (Figures 5a–c, and
Supplementary Figure 1). As we did not observe any
elevation in Akt1 protein expression in these tissues
(Supplementary Figure 1), we suspect that the pan-Akt
antibody has a preference for Akt1, and therefore
cannot be used to accurately measure the reduction in
total Akt proteins.
To further corroborate the effect of Akt2 deﬁciency
on total Akt activity, we used the phosphorylation of
proline-rich protein PRAS40 by Akt as readout for total
Akt activity. Consistently, we found that there was no
signiﬁcant reduction in the phosphorylation of PRAS40
in Pten
þ/ Akt2
 /  tissues with relative to Pten
þ/  tissues,
except in the thyroid (Figure 5e).
Akt2
 /  mice have over a 10-fold higher level of
insulin than wild-type level because they display insulin
resistance (Chen et al., 2009). In Pten
þ/ Akt2
 /  mice,
insulin level is reduced compared with Akt2
 /  mice
(Chen et al., 2009), but when compared with Pten
þ/ 
mice, insulin level is elevated about sixfold in male
mice and a little more than threefold in female mice
(Figure 6a). Therefore, the discrepancy between the
expected reduction in total Akt activity after Akt2
deletion in Pten
þ/  mice could also be explained by the
Figure 3 Effect of Akt2 deﬁciency on tumor development in the adrenal gland and on the number of polyps in the small intestine of
Pten
þ/– mice. (a) The diameter of the adrenal glands in 9-month-old female or 12-month-old male, Pten
þ/–, Pten
þ/–Akt2
–/– and wild-
type mice. The numbers of mice are indicated in parentheses. (b) Quantiﬁcation of BrdU incorporation in the adrenal medulla of
Pten
þ/– and Pten
þ/–Akt2
–/– mice. BrdU analysis was carried out as described in Figure 1b. (c) The deﬁciency of Akt2 did not reduce the
number of polyps in the small intestine of Pten
þ/– mice. Quantiﬁcation of the number of intestinal polyps in 9-month-old female and
12-month-old male mice. The number of polyps±s.d. per mouse is shown. The numbers of mice are indicated in parentheses
(F, female; M, male).
Figure 4 Akt2 deﬁciency in Pten
þ/  reduces the incidence of
neoplastic lesions in the thyroid. Incidence of neoplastic lesions in
thyroid glands derived from Pten
þ/–, Pten
þ/–Akt2
–/– and wild-type
12-month-old male and 9-month-old female mice. The numbers of
mice are indicated in parentheses.
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Oncogenerelatively high blood insulin level in Pten
þ/ Akt2
 / 
mice, which elevates the activity of the other two Akt
isoforms. To conﬁrm this assumption we measured
tyrosine 608 phosphorylation of insulin receptor sub-
strate-1, as readout for insulin receptor activity. The
phosphorylated tyrosine 608 binds and activates phos-
phatidylinositol 3-kinase. We found that indeed in
Pten
þ/ Akt2
 /  tissues pTyr608 is markedly elevated
when compared with Pten
þ/  tissues (Figure 6b). We
therefore concluded that the relatively lower expression
of Akt2 versus Akt1 in combination with the high level
of insulin signaling in Pten
þ/ Akt2
 /  mice prohibited a
marked reduction in tumorigenesis in these mice.
Discussion
Previous results showed that Akt1 deletion alone was
sufﬁcient to signiﬁcantly attenuate tumor develop-
ment in Pten
þ/  mice, and in many cases even the
haplodeﬁciency of Akt1 signiﬁcantly attenuated the
development of tumors in Pten
þ/  mice (Chen et al.,
2006). By contrast, the results described above showed
that Akt2 deﬁciency is not sufﬁcient to inhibit sig-
niﬁcantly the development of tumors in Pten
þ/ ,
except in the thyroid. One possibility is that the relative
expression of Akt1 versus Akt2 in the different tissues
determines their differential effect on tumorigenesis.
Figure 5 The deletion of Akt2 in Pten
þ/  mice did not signiﬁcantly reduce total Akt activity except in the thyroid. Six- to nine-month-
old female and male mice were killed and pAkt was assessed by immunoblotting of proteins extracted from various tissues. (a) Left
panel —representative immunoblot showing the level of Akt phosphorylated at Ser473, in prostate tissues isolated from Pten
þ/ 
and Pten
þ/ Akt2
 /  mice. The immunoblot was also subjected to anti-Akt2 antibodies and anti-pan Akt antibodies. Right panel—
immunohistochemistry, using anti-pS473-Akt, of histological sections from the anterior and dorsolateral prostate lobes of Pten
þ/ 
and Pten
þ/ Akt2
 /  mice. (b) Representative immunoblot showing the level of Akt phosphorylated at Ser473 in uteri isolated from
Pten
þ/  and Pten
þ/ Akt2
 /  mice. The immunoblot was also subjected to anti-Akt2 antibodies and anti-pan Akt antibodies.
(c) Representative immunoblot showing the level of Akt phosphorylated at Ser473 in thyroids isolated from Pten
þ/  and Pten
þ/ 
Akt2
 /  mice. The immunoblot was also subjected to anti-Akt2 antibodies and anti-pan Akt antibodies. (d) Quantiﬁcation of
pAkt/tubulin ratio in prostate samples from three Pten
þ/  and Pten
þ/ Akt2
 /  mice, in uteri from six Pten
þ/  and four Pten
þ/ 
Akt2
 /  mice, in the adrenal glands from six Pten
þ/  and ﬁve Pten
þ/ Akt2
 /  mice, and in the thyroids from ﬁve Pten
þ/  and Pten
þ/ 
Akt2
 /  mice. (e) Representative immunoblot showing phosphorylation of PRAS40 at threonine 246 by Akt. G6PD was used as
a loading control. (f) Quantiﬁcation of Akt1 versus Akt2 mRNA expression using q-PCR (Chen et al., 2006).
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OncogeneIn tissues such as prostate, uterus and intestine, in which
the predominantly expressed Akt isoform is Akt1, Akt2
deletion does not appear to signiﬁcantly or markedly
affect tumor development in Pten
þ/  mice. In these
tissues, Akt1 deletion markedly and signiﬁcantly atte-
nuated tumor development. In the thyroid in which
Akt2 deletion markedly attenuated tumor development,
Akt2 is the predominantly expressed Akt isoform. Thus,
at a glance, the differential effect of the deletion of the
two Akt isoforms on tumorigenesis in Pten
þ/  mice is
correlated with their relative level of expression. How-
ever, as indicated above, even the haplodeﬁciency of
Akt1 was sufﬁcient to markedly attenuate the develop-
ment of neoplasia in the prostate, endometrium and
intestine. Thus, on the basis of the relative expression of
Akt1 and Akt2 in these tissues, Akt2 deletion is expected
to reduce total Akt activity to the same extent as the
haplodeﬁciency of Akt1. Consequently Akt2 deletion is
expected to have a similar effect on tumor development
to that observed by the Akt1 haplodeﬁciency. Further-
more, although Akt2 is the major Akt isoform expressed
in the thyroid, Akt2 deﬁciency reduced tumor develop-
ment in the thyroid by the same extent achieved by Akt1
deﬁciency (Chen et al., 2006).
The inability of Akt2 deﬁciency to efﬁciently inhibit
tumor development, as should be expected, based on
its relative expression, could be due to the relatively
high level of blood insulin in Pten
þ/ Akt2
 /  mice. The
high levels of insulin in Akt2
 /  mice prohibited the
reduction in total Akt activity as it elevated the activity of
the two remaining Akt isoforms. Total Akt activity was
markedly reduced by Akt2 deletion in Pten
þ/  thyroid
consistent with twofold higher level of Akt2 versus Akt1
in the thyroid. However, on the basis of the relative level
of expression it is expected that total Akt activity in
the Pten
þ/ Akt2
 /  thyroid should be reduced by about
two-third. Supporting this possibility are the ﬁndings
of an association of hyperinsulinemia with increased
incidence of neoplasia in several animal models of cancer
(Gallagher and LeRoith, 2010; Novosyadlyy et al.,2 0 1 0 ) .
The hyperinsulinemia in Akt2
 /  mice may also explain
the observed acceleration of mammary gland tumor
development by Akt2 deletion in mouse models for breast
cancer (Maroulakou et al.,2 0 0 7 ) .
Cell autonomous functional differences between Akt1
and Akt2 that could account for the differences between
the effects of Akt1 and Akt2 deletion on tumor develop-
ment in Pten
þ/  cannot be completely excluded. Indeed,
functional differences between Akt1 and Akt2 were
reported (Irie et al., 2005; Iliopoulos et al., 2009).
Further studies using cell type-speciﬁc conditional
knockouts of Akt2 are required to determine whether
the inability of Akt2 deletion to inhibit tumor develop-
ment is cell autonomous.
The results presented here have implications for
cancer therapy. The results suggest that the ablation of
Akt2 will not be beneﬁcial for cancer therapy in general
but could be beneﬁcial for certain types of cancers in
which Akt2 is the major Akt-expressed isoform, such as
thyroid cancer in which it was reported to have a
particular role in pathogenesis and progression (Ringel
et al., 2001). Inhibitors of Akt that markedly inhibit
Akt2 may not be useful for prostate and endometrial
cancers that have dysfunctional PTEN, unless they also
markedly inhibit Akt1. Ideally, selective inhibitors of
Akt1 should be used for the treatment of prostate and
endometrial cancers that display dysfunctional PTEN.
The recent development of small-molecule inhibitors
that preferentially inhibit Akt1 (Li et al., 2009; Lindsley,
2010) could address this issue.
Figure 6 Akt2-deﬁciency in Pten
þ/  mice elevates blood insulin levels and phosphorylation insulin receptor substrate-1 on tyrosine
608. (a) Serum insulin level was measured in 6-month-old WT, Pten
þ/  (P
þ/ ), and Pten
þ/ Akt2
 /  mice as described in Materials
and methods. Number of mice is indicated. Bars represent the s.e.m. (b) Representative immunoblot showing the phosphorylation
of insulin receptor substrate-1 on tyrosine 608. G6PD was used as a loading control.
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OncogeneMaterials and methods
Mice
Pten
þ/  mice and Akt2
 /  mice used in these studies are in
C57BL6 background and were previously described (Chen
et al., 2006, 2009).
Histology and immunohistochemistry
The prostate or uterus, adrenal gland, small and large intestine
and thyroid were harvested and tissues were ﬁxed by
immersion in 10% buffered formalin, then processed and
embedded in parafﬁn sections (5mm) and subjected to
hematoxylin and eosin, immunoperoxidase or immunoﬂuor-
escence staining. Sections were examined by light microscopy
or Zeiss LSM 510 Meta Confocal microscopy.
Immunohistochemistry was conducted as previously described
(Chen et al., 2006). The following primary antibodies were used:
rabbit anti-pS473-Akt, (Cell Signaling Technology, Danvers,
MA, USA), rabbit anti-PTEN (Biosource, Camarillo, CA, USA),
mouse anti-BrdU (Dako, Carpinteria, CA, USA) and rabbit anti-
cytokeratin 14 (Novocastra Laboratory, Newcastle upon Tyne,
UK). For pAkt and PTEN staining, the related blocking peptide
was mixed with the primary antibody as extra-negative control to
verify the speciﬁcity of these antibodies. Prostate parafﬁn sections
obtained from different genotypes of mice were stained with
anti-K14. The result of staining were scored as follows:
0.0: no detectable positive cell in whole section.
0.5: Few lightly stained slim satellite positive cells.
1.0: Many separated triangles shaped strong positive cells.
2.0: Positive cells attached to each other and form a line at
the base of gland.
3.0: The positive cells are not limited to the base of gland,
and some positive cells are also present inside the gland in
the lumen.
4.0: Strong positive cells composed of variable size of sheets.
BrdU incorporation assay
Mice were given intraperitoneal injections of 0.5mg BrdU per
10g body weight for 1h before killing. After dewax and
rehydration, the parafﬁn sections were digested by pepsin
followed by digestion with EcoR1 and Exonuclease III. Slides
were then incubated with anti-BrdU and processed for
immunohistochemistry. BrdU-labeled cells were counted from
ﬁve ﬁelds at  250 magniﬁcation for prostate and uterus and
 400 magniﬁcation for adrenal medulla. All counts were
taken from the highest labeled area of all sections.
Measurement of the size of adrenal and adrenal medulla
The longest diameter of adrenal was recorded and the images of
adrenal were taken by using confocal microscopy according to
the different intensity of autoﬂuorescence from eosin to distin-
guish the cortex and medulla area. An arbitrary number of the
size of medullary areas was obtained by using Image J software.
Immunoblotting
For immunoblotting, tissues were grounded and lysed in 200ml
of lysis buffer (20mM Tris–HCl, pH 7.5), 100mM KCl, 20mM
glycerol phosphate, 1mM dithiothreitol, 0.25mM Na3VO4,
10mM NaF, 1mM EDTA, 1mM EGTA, 1mM phenylmethyl-
sulfonyl ﬂuoride, 10mM sodium pyrophosphate, 10nM okadaic
acid and proteinase inhibitor cocktail (Complete mini from
Roche Applied Science, Indianapolis, IN, USA) was added.
Insoluble materials were removed by centrifugation. Samples
were subjected to immunoblotting using anti-pS473-Akt, anti-
pan-Akt, anti-Akt1, anti-Akt2 and anti-pT246-PRAS40 anti-
bodies from Cell Signaling, and anti-pTyr608-insulin receptor
substrate-1 antibody from Millipore (Billerica, MA, USA).
Measurement of insulin levels
Serum insulin levels were measured as described previously
(Chen et al., 2009), using enzyme-linked immunosorbent assay
(Millipore, Cat.# EZRMI-13K) according to the manufac-
turer’s instructions.
Data analysis
Data were entered into Microsoft EXCEL spreadsheet.
P-values were calculated with Student’s t-test. Error bars
represent s.d.
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